Informations générales (source: ClinicalTrials.gov)

NCT03606070 Statut inconnu
Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study
Interventional
  • Carcinome pulmonaire non à petites cellules
N/A
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
novembre 2017
novembre 2020
08 septembre 2025
To estimate the intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping in locally advanced and trace mestastatic non-small cell lung cancer (NSCLC).
 Voir le détail

Etablissements

Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CLCC INSTITUT GUSTAVE ROUSSY Caroline CARAMELLA, MD En recrutement IDF Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

1. Locally advanced NSCLC (stages IIB, IIIA or IIIB of the TNM classification 7th
edition) or trace metastatic stage IV (</=5 mestastasis, </= 3 organ reached)

2. Exclusive therapeutic management by concomitant radio-chemotherapy administered in
accordance with international recommendations (dual therapy with platinum salts)

3. Signed consent

4. Patients affiliated with the social security scheme or beneficiary of a similar
scheme.


1. Minor

2. Pregnant / lactating woman

3. Person deprived of liberty by judicial or administrative decision, adults who are
the subject of a legal protection measure or unable to express their consent

4. Previous cancer in the 2 years prior to registration

5. Previousradiotherapy / thoracic surgery

6. Patients under experimental treatment or for whom the administration of an
experimental treatment is planned

7. Claustrophobic patients

8. Severe Renal Insufficiency (Clearance MDRD Cockroft <30ml / min)

9. Uncontrolled diabetes, hyperglycemia> 1.8g / L

10. Patient with metallic implants not compatible with MRI or any immovable implanted
electronic medical device (eg pacemaker, neurostimulator, cochlear implants, etc.)